N
KALA icon

Nuveen’s KALA BIO KALA Stock Holding History

Nuveen’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-65
Closed -$250K – 3375
2022
Q1 		$250K Hold
65
– – ﹤0.01% 3152
2021
Q4 		$221K Sell
65
-2
-3% -$9.28K ﹤0.01% 3226
2021
Q3 		$520K Sell
67
-6
-8% -$51.8K ﹤0.01% 3162
2021
Q2 		$963K Sell
73
-41
-36% -$645K ﹤0.01% 3023
2021
Q1 		$1.92M Buy
114
+18
+19% +$351K ﹤0.01% 2638
2020
Q4 		$1.63M Buy
96
+33
+52% +$621K ﹤0.01% 2610
2020
Q3 		$1.18M Sell
63
-42
-40% -$965K ﹤0.01% 2614
2020
Q2 		$2.77M Buy
105
+33
+46% +$935K ﹤0.01% 2198
2020
Q1 		$1.58M Buy
72
+2
+3% +$32K ﹤0.01% 2299
2019
Q4 		$648K Buy
70
+30
+75% +$290K ﹤0.01% 2841
2019
Q3 		$376K Sell
40
-22
-35% -$268K ﹤0.01% 3014
2019
Q2 		$989K Buy
+62
New +$1.03M ﹤0.01% 2742

Other funds holding KALA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Nuveen's KALA Position: Q2 2022 in Review

Nuveen sold out of KALA BIO (KALA) in Q2 2022, closing a stake of 65 shares — an estimated $250K sold.

Nuveen first reported a position in KALA in Q2 2019 and held it in 12 quarters. The position peaked at $2.77M in Q2 2020. 63 funds tracked by Wall St. Rank hold KALA as of Q2 2022.

  • Nuveen reported no remaining KALA BIO position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 65 KALA BIO shares in Q2 2022, an estimated $250K.
  • Nuveen first reported a position in KALA BIO in Q2 2019 and held it in 12 quarters.
  • Nuveen's KALA BIO position peaked at $2.77M in Q2 2020.
  • 63 funds tracked by Wall St. Rank held KALA BIO as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.